Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France

NCT07691424 | Not Yet Recruiting

• 2 other identifiers: RNI 2025 ZAGHDOUDIANSM
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival . The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.

Conditions

HIV - Human Immunodeficiency Virus; Socio-economic Status; Migrants

Keywords

HIV; socio-economic status; vulnerability; immuno-virological status; migrants

Outcome Measures

Primary Outcomes (1)

• HIV immuno-virological status

  To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants

  Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adults patients living with HIV and receiving care at Clermont-Ferrand Univeristy Hospital between 2010 and 2022

You may qualify if:

• Adults (≥18 years of age);
• Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France.
• Patients who declined to participate in the study;
• Patients who do not speak French and for whom no interpretere was available
• Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)

Sponsors & Collaborators

• University Hospital, Clermont-Ferrand: lead

Study Sites (1)

Clermont-Ferrand University Hospital

Clermont-Ferrand, France, 63000, France

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Aida ZAGHDOUDI

  University Hospital, Clermont-Ferrand

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lise Laclautre

CONTACT

+33473754963; promo_interne_drci@chu-clermontferrand.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2026
• First Posted: July 8, 2026
• Study Start: July 15, 2026
• Primary Completion (Estimated): February 15, 2029
• Study Completion (Estimated): February 15, 2030
• Last Updated: July 8, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)